Seres Therapeutics (MCRB) Competitors $19.44 +1.12 (+6.11%) Closing price 04:00 PM EasternExtended Trading$19.39 -0.05 (-0.26%) As of 05:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MCRB vs. TRML, ORKA, TYRA, RZLT, ANAB, KOD, XNCR, SAGE, RAPP, and SNDLShould you be buying Seres Therapeutics stock or one of its competitors? The main competitors of Seres Therapeutics include Tourmaline Bio (TRML), Oruka Therapeutics (ORKA), Tyra Biosciences (TYRA), Rezolute (RZLT), AnaptysBio (ANAB), Kodiak Sciences (KOD), Xencor (XNCR), Sage Therapeutics (SAGE), Rapport Therapeutics (RAPP), and SNDL (SNDL). These companies are all part of the "pharmaceutical products" industry. Seres Therapeutics vs. Its Competitors Tourmaline Bio Oruka Therapeutics Tyra Biosciences Rezolute AnaptysBio Kodiak Sciences Xencor Sage Therapeutics Rapport Therapeutics SNDL Seres Therapeutics (NASDAQ:MCRB) and Tourmaline Bio (NASDAQ:TRML) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends. Is MCRB or TRML more profitable? Tourmaline Bio's return on equity of -30.50% beat Seres Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Seres TherapeuticsN/A -350.16% -67.69% Tourmaline Bio N/A -30.50%-29.63% Which has preferable valuation & earnings, MCRB or TRML? Tourmaline Bio is trading at a lower price-to-earnings ratio than Seres Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSeres TherapeuticsN/AN/A$140K-$4.60-4.23Tourmaline BioN/AN/A-$73.21M-$3.43-6.80 Do insiders & institutionals hold more shares of MCRB or TRML? 59.3% of Seres Therapeutics shares are held by institutional investors. Comparatively, 91.9% of Tourmaline Bio shares are held by institutional investors. 4.7% of Seres Therapeutics shares are held by insiders. Comparatively, 13.0% of Tourmaline Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Which has more volatility & risk, MCRB or TRML? Seres Therapeutics has a beta of 2.9, meaning that its share price is 190% more volatile than the S&P 500. Comparatively, Tourmaline Bio has a beta of 2.04, meaning that its share price is 104% more volatile than the S&P 500. Do analysts rate MCRB or TRML? Seres Therapeutics presently has a consensus price target of $73.67, suggesting a potential upside of 278.94%. Tourmaline Bio has a consensus price target of $50.14, suggesting a potential upside of 115.11%. Given Seres Therapeutics' higher possible upside, equities research analysts clearly believe Seres Therapeutics is more favorable than Tourmaline Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Seres Therapeutics 2 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.75Tourmaline Bio 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media prefer MCRB or TRML? In the previous week, Tourmaline Bio had 23 more articles in the media than Seres Therapeutics. MarketBeat recorded 24 mentions for Tourmaline Bio and 1 mentions for Seres Therapeutics. Seres Therapeutics' average media sentiment score of 0.84 beat Tourmaline Bio's score of 0.39 indicating that Seres Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Seres Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tourmaline Bio 5 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryTourmaline Bio beats Seres Therapeutics on 8 of the 13 factors compared between the two stocks. Get Seres Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MCRB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MCRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MCRB vs. The Competition Export to ExcelMetricSeres TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$170.20M$3.09B$5.82B$9.74BDividend YieldN/A2.23%3.84%4.09%P/E Ratio-4.2321.1431.1525.97Price / SalesN/A399.83475.57123.18Price / CashN/A43.0937.1558.38Price / Book5.178.079.116.39Net Income$140K-$54.72M$3.26B$265.66M7 Day Performance16.48%2.62%2.11%1.98%1 Month Performance56.90%7.63%5.12%1.33%1 Year Performance13.02%13.11%31.25%21.15% Seres Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MCRBSeres Therapeutics3.2935 of 5 stars$19.44+6.1%$73.67+278.9%+4.8%$170.20MN/A-4.23330TRMLTourmaline Bio2.4324 of 5 stars$22.17-1.8%$50.14+126.2%+58.4%$579.72MN/A-6.4644ORKAOruka Therapeutics2.3763 of 5 stars$15.25-0.8%$40.38+164.8%N/A$575.62MN/A-5.43N/AAnalyst RevisionTYRATyra Biosciences2.3759 of 5 stars$10.81+0.7%$30.83+185.2%-48.4%$569.66MN/A-6.0720News CoverageAnalyst ForecastRZLTRezolute3.2592 of 5 stars$6.55+0.8%$12.20+86.3%+60.0%$565.47MN/A-5.7040ANABAnaptysBio3.0707 of 5 stars$20.02-0.6%$46.13+130.4%-46.1%$563.86M$91.28M-4.47100KODKodiak Sciences3.2361 of 5 stars$11.25+6.4%$11.75+4.4%+248.0%$558.33MN/A-2.9690Analyst RevisionXNCRXencor3.5274 of 5 stars$7.81+1.7%$26.43+238.4%-57.2%$547.76M$110.49M-3.25280News CoverageAnalyst ForecastSAGESage Therapeutics3.474 of 5 stars$8.68flat$7.85-9.6%N/A$543.54M$41.24M-1.78690RAPPRapport Therapeutics1.7637 of 5 stars$14.59-0.7%$29.50+102.2%-33.6%$536.70MN/A-5.84N/ASNDLSNDL1.8281 of 5 stars$2.16+6.9%$4.00+85.2%+6.2%$530.81M$671.81M-8.002,516 Related Companies and Tools Related Companies TRML Competitors ORKA Competitors TYRA Competitors RZLT Competitors ANAB Competitors KOD Competitors XNCR Competitors SAGE Competitors RAPP Competitors SNDL Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MCRB) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon Musk’s New TechnologyElon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a n...Paradigm Press | SponsoredNew law could create $3.7 trillion tsunami.During a meeting in Washington D.C., Jeff Brown discovered a bold initiative. He calls it “President Trump’...Brownstone Research | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seres Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Seres Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access